Clinical Trial Update: A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain [Phase 3]

View source ↗

Summary

A Phase 3 study assessing the effectiveness and safety of Tapentadol extended-release for moderate to severe chronic low back pain; the trial is completed and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low Back Pain

Drugs mentioned

• Tapentadol ER (Tapentadol)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Low Back Pain | Phase 3 | Status: COMPLETED | Results posted: 2010-06-24